Not Rated Nephrocare Health Services Ltd For Target Not Rated by Choice Institutional Equities Ltd
NEPHROPL is building the company for scale through disciplined, repeatable economics rather than one-off wins: This view was reinforced after our interaction with NEPHROPL management. The company stands out as one of India's few organised dialysis-care platforms with credible depth across hospital outsourcing, standalone clinics and cross-border PPP contracts.
In our view, NEPHROPL is positioned to ride the twin tailwinds of India's under-penetrated dialysis-outsourcing opportunity and the structural global shift from captive hospital units towards standalone clinics. Management's 15–20% revenue CAGR guidance over the next 3–4 years looks achievable, anchored by 40–50 new hospital conversions annually against a ~3,000-hospital addressable base. Saudi Arabia tender is the next major catalyst and Kazakhstan also offering additional optionality.
The balance between growth and profitability was notable: EBITDA margin is guided down, from ~23% to ~21%, even as the company absorbs newmarket investment, supported by a debt-free balance sheet with ~INR 475 Cr cash. The long-term aspiration is backed by proven execution and steady capex discipline.
Clinic Formats: The network operates via three models. Captive clinics (272 clinics) are located inside private hospitals such as Max Super Specialty, Fortis Escorts and Care Hospitals, under 7–15-year revenue-sharing tenors. PPP (Public-Private Partnership) clinics (200 clinics) operate inside government hospitals across states, such as Andhra Pradesh, Bihar, Uttarakhand and Karnataka, under 5–10-year renewable terms with no revenue/rent share. Standalone clinics (78 clinics) operate independently outside hospitals in high-demand areas on a rental basis. Overall, ~52% of clinics function under this asset-light, revenue-sharing model, enabling low upfront capital investment.
Domestic Operations: In India, NEPHROPL serves 33,000+ guests through 487 clinics spanning 307 cities, with ~80% of clinics in Tier II/III cities and towns, contributing ~75% revenue salience from these regions. The company has expanded guest volumes at a ~17.4% CAGR and treatment volumes at ~18.9% CAGR (FY23–Q1FY27).
International Operations: NEPHROPL's key growth engine beyond India, with the Company expanding its proven dialysis operating model across markets including the Philippines, Uzbekistan, Nepal and Saudi Arabia. International revenue contribution increased, from 31.8% in FY25 to 41.8% in FY26, supported by higher treatment volumes and significantly higher revenue per treatment in international markets. The Philippines is the Company's largest international market, with 51 clinics, while Uzbekistan has 6 clinics. The Company follows a disciplined country-selection framework based on demand depth, reimbursement and policy viability, political and regulatory stability, and clarity on cash repatriation.
Technology & Clinical Platform: NEPHROPL is also strengthening its distributed dialysis network through technology-led clinical and operational monitoring. Its proprietary Reformmed.AI platform had been implemented across 50 clinics as of FY26, with the objective of monitoring key operational parameters and improving clinical outcomes. This technology layer, combined with standardised clinical protocols and a scalable operating model, supports consistent service delivery across the Company's geographically distributed network.
Growth & Ownership: Strategy rests on five pillars, consolidating India leadership, scaling up PH/UZ/KSA, entering new markets, leveraging scale for profitability and innovation-led digital healthcare. Shareholding comprises 63.9% Promoter and remaining with marquee institutional investors including SBI Mutual Fund, ICICI Mutual Fund, Fidelity, Polar Capital, IFC and Investcorp.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
